ACTINIUM PHARMACEUTICALS INC (ATNM)

US00507W2061 - Common Stock

1.77  -0.09 (-4.84%)

After market: 1.76 -0.01 (-0.56%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (9/16/2024, 8:04:00 PM)

After market: 1.76 -0.01 (-0.56%)

1.77

-0.09 (-4.84%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-80.76%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap55.14M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ATNM Daily chart

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The firm focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The firm holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Company Info

ACTINIUM PHARMACEUTICALS INC

100 Park Ave., 23Rd Floor

New York City NEW YORK 10016

P: 16466773870

CEO: Sandesh Seth

Employees: 49

Website: https://www.actiniumpharma.com/

ATNM News

News Image7 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such...

News Image13 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such...

News Image21 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such...

News Imagea month ago - Bronstein, Gewirtz & Grossman, LLCActinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
News Imagea month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such...

News Imagea month ago - Bronstein, Gewirtz & Grossman, LLCActinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

ATNM Twits

Here you can normally see the latest stock twits on ATNM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example